Form 4: Pressure BioSciences Director Acquires Shares Through Interest Payment

Kevin Pollack, a director at Pressure BioSciences Inc, acquired 2,914 shares of common stock on March 27, 2024, through interest paid on convertible preferred stock.

Summary

• On March 27, 2024, Kevin Pollack, a director of Pressure BioSciences Inc. (PBIO), acquired 2,914 shares of common stock.
• The acquisition was a result of interest paid on convertible preferred stock.
• The price per share was $0.16.
• Following the transaction, Pollack directly owns 36,787 shares of PBIO common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of a director acquiring shares through interest payment. It doesn't inherently indicate positive or negative sentiment, but insider buying can sometimes be interpreted as a positive signal.

Positives

• Director Kevin Pollack's acquisition of shares may signal confidence in the company's future.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC when a company insider, such as a director, buys or sells shares of their company's stock. It provides transparency to the market regarding insider transactions.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as insider buying is often seen as a sign of confidence in the company.

Key Dates

Keywords

Pressure BioSciences Inc, PBIO, Kevin Pollack, Director, Share Acquisition, Common Stock, Convertible Preferred Stock, Interest Payment, Form 4